7.12  0.08 (1.14%)		04-25 16:00
Open: 6.69 High: 7.55 Volume: 275,209		Pre. Close: 7.04 Low: 6.69 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	10.61	1-year :	15.41
Resists	First :	9.08	Second :	13.19
Pivot price	4.89
Supports	First :	2.43	Second :	2.02
MAs	MA(5) :	6.34	MA(20) :	4.47
	MA(100) :	4.8	MA(250) :	5.89
MACD	MACD :	0.6	Signal :	0.2
%K %D	K(14,3) :	39	D(3) :	39.5
RSI	RSI(14): 67.1
52-week	High :	31.45	Low :	0.23

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ TIVC ] has closed below upper band by 9.2%. Bollinger Bands are 27.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	7.56 - 7.59	7.59 - 7.61
Low:	6.62 - 6.65	6.65 - 6.68
Close:	7.07 - 7.12	7.12 - 7.16

Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

Tue, 22 Apr 2025
Sector Update: Health Care - marketscreener.com

Tue, 22 Apr 2025
Tivic Health Systems Stock Is On Fire Today: What's Going On? - Benzinga

Tue, 22 Apr 2025
Tivic Health Stock Doubles After Briefings To Senior Leadership At White House, FDA: But Retail Stays Bearish - MSN

Tue, 22 Apr 2025
Tivic Health Systems soars after meetings with White House, FDA - TradingView

Tue, 22 Apr 2025
Tivic Health Reports White House Briefing and FDA Meetings Secured Positive Interest in Potential Military and Defense Applications of Its Product Candidates - Business Wire

Tue, 15 Apr 2025
Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	1 (M)
Shares Float	1 (M)
Held by Insiders	0.1 (%)
Held by Institutions	2.3 (%)
Shares Short	22 (K)
Shares Short P.Month	212 (K)

EPS	-19.68
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.55
Profit Margin	0 %
Operating Margin	-857.3 %
Return on Assets (ttm)	-88.9 %
Return on Equity (ttm)	-185 %
Qtrly Rev. Growth	-49.6 %
Gross Profit (p.s.)	0
Sales Per Share	1.27
EBITDA (p.s.)	-9.25
Qtrly Earnings Growth	0 %
Operating Cash Flow	-6 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-0.37
PEG Ratio	0
Price to Book value	1.56
Price to Sales	5.59
Price to Cash Flow	-0.77

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.